RecallDepth
Class II Ongoing

Duloxetine Delayed-Release Capsules, USP, 60 mg, a.) 90-count bottle (NDC: 51991-748-90), b.)1000-count bottle (NDC 51991-748-10),Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain; Dist. by: Breckenridge Pharmaceutical, Inc., Berkeley Heights, NJ 07922.

This recall is currently active, issued November 5, 2025. It was issued by Breckenridge Pharmaceutical, Inc..

Company
Breckenridge Pharmaceutical, Inc.
Recall Initiated
October 9, 2025
Posted
November 5, 2025
Recall Number
D-0100-2026
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
172,263 bottles
Firm Location
Berkeley Heights, NJ, United States
Official Source
View on FDA website ↗

Reason for Recall

CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.

Distribution

U.S. Nationwide

Lot / Code Info

90-count- Lot # 240721C; Exp. 02/28/2027 1000-count- Lot #230286C; Exp.02/28/2026

More recalls by Breckenridge Pharmaceutical, Inc.

View all recalls by this company →

Other recent Class II Drug recalls